# Semaglutide and Kidney Outcomes in SELECT, FLOW and SOUL | Buy This GLP

A pooled analysis of SELECT, FLOW and SOUL found a kidney composite hazard ratio of 0.84 across 30,787 people, and 0.80 with cardiovascular death excluded.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/are-glp1-drugs-safe-for-your-kidneys
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# Semaglutide and Kidney Outcomes in SELECT, FLOW and SOUL

Pooled across 30,787 people in three trials, semaglutide cut major kidney outcomes to a hazard ratio of 0.84. Take cardiovascular death out and it is 0.80.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20268 min readUpdated November 2026

Pooled across 30,787 participants · primary composite · includes CV death · 0.84 · kidney only · excludes CV death · 0.8 · 1.0

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   Three large randomized trials were pooled at participant level: 30,787 people, mean follow-up over three years.
-   The primary kidney composite favored semaglutide: 973 events against 1,134, hazard ratio 0.84, 95% CI 0.77 to 0.91.
-   That composite counts cardiovascular death as one of its four components.
-   Excluding cardiovascular death, the kidney-only result held: 347 events against 416, hazard ratio 0.80, 95% CI 0.69 to 0.92.
-   The pool mixes 1.0 mg injected, 2.4 mg injected and 14 mg oral semaglutide across three trials with different enrollment criteria.

The pooled evidence concerns kidney outcomes with semaglutide in the people enrolled in three trials. The randomized trials were pooled at participant level, covering 30,787 people over more than three years. The primary kidney composite favored semaglutide. There were 973 events against 1,134, a hazard ratio of 0.84.

That composite counts cardiovascular death as one of four components. Strip it out and the kidney-only result holds. It ran 347 events against 416, hazard ratio 0.80.

The [guide to GLP-1 medicines after a kidney transplant](https://buythisglp.com/research/can-you-take-a-glp1-after-a-kidney-transplant) summarizes observational studies in transplant recipients. A separate FLOW analysis broke down the result by stage of chronic kidney disease [\[2\]](https://buythisglp.com/research/are-glp1-drugs-safe-for-your-kidneys#ref-2).

A [German cost-effectiveness model](https://buythisglp.com/research/the-best-kidney-result-lost-on-the-money) projected the greatest gain in quality-adjusted survival for tirzepatide and the highest direct costs among the options modeled [\[3\]](https://buythisglp.com/research/are-glp1-drugs-safe-for-your-kidneys#ref-3). Those projections reflect German health-system assumptions and do not establish clinical superiority in a head-to-head kidney trial.

## What was pooled

Participant-level data from SELECT, FLOW and SOUL, prespecified rather than assembled afterward. [\[1\]](https://buythisglp.com/research/are-glp1-drugs-safe-for-your-kidneys#ref-1) One trial enrolled people with chronic kidney disease and used 1.0 mg semaglutide by weekly injection. One enrolled people with established atherosclerotic cardiovascular disease and used 2.4 mg weekly by injection. The third enrolled adults with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both. It used 14 mg of oral semaglutide daily. Together, 30,787 participants with a mean follow-up between 39.5 and 47.5 months.

## What the primary outcome measured

The primary endpoint was a composite. A persistent 50% or greater fall in kidney filtration, kidney failure, kidney-related death, or cardiovascular death. On that, 973 first events occurred on semaglutide against 1,134 on placebo. The hazard ratio was 0.84, 95% CI 0.77 to 0.91.

Cardiovascular death contributed to the first-event count alongside the kidney outcomes. The researchers also analyzed a narrower composite that excluded cardiovascular death.

Kidney outcomes excluding cardiovascular death

The secondary composite excluded cardiovascular death. It recorded 347 first events with semaglutide and 416 with placebo, for a hazard ratio of 0.80 (95% CI 0.69 to 0.92). This estimate uses fewer events and has a wider confidence interval than the primary composite.

## What the pooled estimate can tell us

The pooled hazard ratio summarizes three trials with different enrollment criteria, doses and routes. It does not establish an equivalent kidney benefit for oral and injected semaglutide.

It matters commercially because the two formats are not priced alike here. Take only the 14 sellers publishing a figure for both, read November 2026. The tablet runs a median of $34 more a month than the injection. Of those sellers, 8 charge more for it. Whether that gap reflects anything about outcomes is exactly what nobody has tested, and [the price check](https://buythisglp.com/tools/glp1-price-check) shows the current spread.

## Who funded it, and who it describes

Novo Nordisk funded the pooled analysis. The researchers specified the analysis in advance.

The population is people with cardio-kidney-metabolic disease — kidney disease or established cardiovascular disease, mostly with diabetes. If you are buying for weight loss, this describes somebody else’s risk profile. To understand how baseline risk changes the expected benefit, see [how many people have to be treated for one event to be prevented](https://buythisglp.com/research/glp1-number-needed-to-treat). That number depends on the population and follow-up period.

## Frequently asked

Does semaglutide protect the kidneys?

In people with kidney disease or established cardiovascular disease, this pooled analysis found fewer major kidney events — hazard ratio 0.80 on the composite that excludes cardiovascular death, across 30,787 participants.

Why does the composite include cardiovascular death?

Cardiovascular death was a prespecified component of the primary outcome. The authors also reported a secondary result for kidney events alone.

Does the tablet work as well as the injection?

This analysis cannot say. It pooled an oral arm with two injected arms at different doses; nobody compared the formats head to head on kidney outcomes.

Who funded it?

Novo Nordisk, the manufacturer of semaglutide, funded the pooled analysis.

## Sources

1.  \[1\] Mann JFE, et al. (2026). Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis The Lancet Diabetes & Endocrinology. [PMID 42567173](https://pubmed.ncbi.nlm.nih.gov/42567173/)
2.  \[2\] Tuttle K, Mann J, Mayrdorfer M, Rayner B, et al. (2026). Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial Clinical Journal of the American Society of Nephrology. [PMID 41706532](https://pubmed.ncbi.nlm.nih.gov/41706532/)
3.  \[3\] Hille H, Schramm W, Bounekkar A (2026). The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany Cost Effectiveness and Resource Allocation. [PMID 42509550](https://pubmed.ncbi.nlm.nih.gov/42509550/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
